AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
AXIS Capital Holdings Limited
Video analysis: AXS
All videosNo video analysis for this stock yet. Request one from our team.
News: AXS
AXS Joins AVA Presents to Power the Next Chapter of Colorado Springs' Historic CityAud
LOS ANGELES & COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--AXS Joins AVA Presents to Power the Next Chapter of Colorado Springs' Historic CityAud.
New Strong Sell Stocks for September 9th
LKQ, AGCO and AXS have been added to the Zacks Rank #5 (Strong Sell) List on September 9, 2026.
AXIS Celebrates 25th Anniversary, Launches Global Brand Campaign Spotlighting Its Focus on Specialty Underwriting Leadership
PEMBROKE, Bermuda, Sept. 08, 2026 (GLOBE NEWSWIRE) -- AXIS Capital Holdings Limited (“AXIS” or the “Company”) (NYSE: AXS) today unveiled a new brand campaign celebrating its 25-year history of providing specialty insurance and reinsurance solutions to customers. The company was formed in the aftermath of the September 11 tragedy to address a void in the market for specialist capacity. Since its modest beginnings as a start-up, AXIS has grown into a global specialty leader with $35 billion in total assets and $7.7 billion in total capital as of year-end 2025.
Axsome Begins Phase III Study on AXS-05 for Smoking Cessation
AXSM begins dosing in the phase III SUMMIT study investigating AXS-05 for treating smoking cessation in adults.
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the SUMMIT Phase 3 trial of AXS-05 for smoking cessation. SUMMIT (Studying NMDA and Sigma-1 in Smoking Cessation Treatment) is a Phase 3 randomized, double-blind, active- and placebo-controlled, multicenter trial to assess the efficacy and safety of AXS-05 as a smoking cessation treatment in adults.
Why Is Axis Capital (AXS) Down 5.6% Since Last Earnings Report?
Axis Capital (AXS) reported earnings 30 days ago. What's next for the stock?
Axis Capital's Insurance Operations Power Diversified Growth
AXS' Insurance segment drives premium growth through specialty underwriting, product diversification and disciplined risk selection.
AXS PFD E Offers Competitive Yield Versus Other Insurance Companies
AXIS Capital Holdings Limited offers diversified specialty insurance and reinsurance, with strong A+ credit ratings and a BBB-rated preferred stock AXS.PR.E. AXS reported 15% YOY growth in both premiums written and diluted book value, with a solid 93.1% combined ratio, though reinsurance premiums declined 25%. The fixed-rate, non-cumulative Series E preferred AXS.PR.E offers QDI-eligible dividends and BBB credit quality, appealing for income-focused investors seeking stability.
Similar companies
-
Arch Capital Group Ltd.
ACGL
·
NASDAQ
Compare
-
The Hanover Insurance Group, Inc.
THG
·
New York Stock Exchange
Compare
-
RenaissanceRe Holdings Ltd.
RNR
·
New York Stock Exchange
Compare
-
RLI Corp.
RLI
·
New York Stock Exchange
Compare
-
The Allstate Corporation
ALL
·
New York Stock Exchange
Compare
-
Lincoln National Corporation
LNC
·
New York Stock Exchange
Compare